Ligand validation:6IK5

GAL: beta-D-galactopyranose

GAL is a Ligand Of Interest in 6IK5 designated by the Author

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
6IK5_GAL_B_804	76%	53%	0.128	0.965	0.69	1.12	-	1	1	0	100%	1
6IK5_GAL_A_804	74%	39%	0.103	0.931	0.95	1.44	1	3	1	0	100%	1
3W5G_GAL_B_805	52%	75%	0.192	0.95	0.45	0.53	-	-	1	0	100%	1
6IK8_GAL_A_806	22%	59%	0.238	0.858	0.65	0.92	-	1	0	0	100%	1
4Z0N_GAL_A_405	100%	74%	0.025	0.991	0.5	0.51	-	-	0	0	100%	1
8VCS_GAL_G_301	100%	29%	0.025	0.993	0.95	1.87	-	3	2	0	100%	1
4WWH_GAL_A_401	100%	64%	0.026	0.99	0.47	0.9	-	-	0	0	100%	1
5ELB_GAL_C_202	100%	58%	0.036	0.992	0.82	0.8	-	-	0	0	100%	0.6
9BES_GAL_A_601	100%	52%	0.037	0.985	0.87	0.98	1	-	0	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.